BioRestorative Therapies
BRTX
12 hedge funds and large institutions have $1.8M invested in BioRestorative Therapies in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more funds holding
Funds holding: 10 → 12 (+2)
1.49% less ownership
Funds ownership: 11.37% → 9.88% (-1.5%)
60% less capital inflows, than outflows
Capital inflows: $151K | Capital outflows: $375K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$99.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$47K |
| 3 |
Tower Research Capital (TRC)
New York
|
+$4.06K |
| 4 |
Morgan Stanley
New York
|
+$86 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$151K |
| 2 |
Boothbay Fund Management
New York
|
-$103K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.2K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$43K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.29K |
BRTX Hedge Fund Activity: Q1 2022 in Review
12 of the 6,362 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2022, worth a combined $1.8M — up 4.7% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BRTX positions and 3 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $99.2K. The largest seller was Ayrton Capital, cutting an estimated $151K.
- 12 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2022, up from 10 in Q4 2021.
- Funds reported $1.8M of BioRestorative Therapies stock for Q1 2022, up 4.7% quarter-over-quarter.
- 5 funds opened new BioRestorative Therapies positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest BioRestorative Therapies buyer in Q1 2022 was Cambridge Investment Research Advisors, an estimated $99.2K added.
- The largest BioRestorative Therapies seller in Q1 2022 was Ayrton Capital, an estimated $151K sold.
Based on aggregated 13F filings for Q1 2022.